A comparison between clenbuterol, salbutamol and terbutaline in relation to receptor binding and in vitro relaxation of equine tracheal muscle.

The research investigates the effectiveness and properties of three beta2-adrenoceptor agonist drugs – clenbuterol, salbutamol and terbutaline – in relaxing equine tracheal muscles, with particular focus on their differing abilities to bind to receptors.

Methodology

• The study takes muscle strips from equine tracheal muscle, precontracted using 40 nM carbachol, and places them in tissue chambers.
• It then compares how salbutamol, terbutaline, and clenbuterol relax these muscle strips, offering a direct comparison of the drugs’ effects.
• The researchers use radioligand binding studies, utilizing a potent beta-adrenoceptor antagonist 125I-cyanopindolol, to examine the drugs’ affinities to the beta2-adrenoceptors in homogenates of the same muscle tissue.

Results

• All three drugs demonstrated similar potency in muscle relaxation. The EC50-values, which represent the concentration of a drug required for 50% of its maximum effect, were calculated as 2.1 nM for clenbuterol, 5.6 nM for salbutamol, and 13.8 nM for terbutaline. All three completely relaxed the muscle strips.
• In terms of receptor binding, clenbuterol showed much lower Kd-value (24 nM), a measurement indicating the strength of the drug-receptor interaction, compared to salbutamol (1100 nM) and terbutaline (3900 nM). In other words, clenbuterol demonstrated a higher affinity for binding with beta2-adrenoceptors.
• Despite clenbuterol’s higher affinity for receptor binding, only 8% of receptors were bound at its EC50-value, compared to less than 1% for the other two drugs. This suggests that clenbuterol has a lower intrinsic efficacy, i.e. its ability to initiate a response after binding to the receptor, than salbutamol and terbutaline.
• The study also reports on beta-adrenoceptor density and the Kd-value of 125I-cyanopindolol.

Conclusions and Implications

• The study provides vital comparative data on the efficacy of three bronchodilator drugs on horse tracheal muscle. It further highlights the relative strengths and weaknesses of these drugs, particularly in terms of receptor binding and subsequent muscle relaxation.
• The lower intrinsic efficacy of clenbuterol, despite its high receptor binding affinity, could have implications for its use in treating chronic obstructive pulmonary disease in horses. This calls for further studies to better understand the implications of these findings in clinical settings and shape effective treatment strategies for equine respiratory conditions.